Resistance to TGF-β1-mediated growth suppression in tumor cells is often associated with the functional loss of TGF-β receptors. Here we describe two B cell lymphoma cell lines (DB and RL) that differ in their sensitivity to TGF-β1−mediated growth suppression. The TGF-β1-resistant cell line DB lacked functional TGF-β receptor II (TβRII) in contrast to the TGF-β-responsive cell line RL, whereas both cell lines had comparable levels of receptor I (TβRI). Lack of functional TβRII was correlated with the lack of TGF-β1-induced nuclear translocation of phospho-Smad3 and Smad2, the lack of nuclear expression of p21
Introduction
Transforming growth factor (TGF)-β1 is a member of the TGF-β superfamily that regulates cell growth and differentiation in a variety of cell types. TGF-β inhibits cell proliferation by arresting cells in G1 phase of the cell cycle. The mechanisms of the cell cycle inhibition depend on the cell type. 1 Some of the critical regulators in this process include p15 INK4b , p21
Cip1/WAF1
, p27, and c-Myc. 1 Activation of the TGF-β receptors (TβR) occurs via ligand-induced heteromeric complex formation of type I and type II serine/threonine kinase receptors. The constitutively active type II receptor then phosphorylates and activates type I receptor, which in turn propagates the TGF-β signal by phosphorylating and activating Smad proteins, Smad2 and Smad3. Receptor-activated Smads (R-Smads) then hetero-oligomerize with a common partner, Smad4, and translocate to the nucleus where, in association with transcriptional co-activators or repressors, they regulate transcription of TGF-β target genes. The termination of TGF-β signaling is achieved, in part, by a feedback mechanism through the induction of inhibitory Smads (I-Smads), e.g., Smad 6 and 7, which then terminate the activation of RSmads. [2] [3] [4] Resistance to TGF-β-mediated growth suppression in tumor cells is often associated with the functional loss of TGF-β receptors and Smads. A frameshift mutation within exon 5 of TβRI has been found in approximately one third of ovarian cancers and is associated with reduced or absent expression of TβRI. 5 Inactivating mutations in TβRI and TβRII have also been reported in human lymphoma 6, 7 and loss of TβRII transcripts and protein has been reported in murine lymphoma. 8 For personal use only. on April 15, 2017 . by guest www.bloodjournal.org From Mutations in the TβRII have been reported in colon and gastric cancers with or without microsatellite instability. [9] [10] [11] [12] [13] Burkitt's lymphoma cell lines and Epstein-Barr virus-transformed B lymphoblastoid cell lines have been shown to harbor reduced expression of TβRII, which correlates with the resistance of these cell lines to TGF-β1. 14 Although Smad2 and Smad4 genes have been shown to be affected in different cancers, no mutation in the Smad3 gene has been found in tumors. 15, 16 In the present study, we examined how B cell lymphoma cells evade TGF-β- For personal use only. on April 15, 2017 . by guest www.bloodjournal.org From
Materials and Methods

Reagents.
For Western blot analysis and immunoprecipitation, rabbit polyclonal anti-TβRI antibody 
Cell Lines and Culture Conditions.
DB and RL cell lines were derived from tumors of patients with diffuse large cell lymphoma. 17 According to the classification of diffuse large B-cell lymphoma (DLBCL) 18, 19 , RL line was considered as Germinal-center B-cell-like based on the t(14:18) chromosomal translocation and higher expression of LMO2. In contrast, no t(14:18) chromosomal translocation, and undetectable level of LMO2 expression were detected in
For personal use only. on April 15, 2017 . by guest www.bloodjournal.org From DB cells. As proliferation signature, c-myc expression was highest in DB cells. Based on these and other signature gene analyses, DB appears to have the "activated B-cell" phenotype. RL and DB cell lines were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2mM L-glutamine, 1,000 U of penicillin/ml, 100 µg of streptomycin/ml. No exogenous growth factors were added. Cells were grown at 37 o C in 5% CO 2 . Fresh growth medium was added to cells every 3 to 4 days until confluent. In all experiments cells were stimulated with either 0.15ng/ml PMA and/or 10ng/ml recombinant TGF-β1 in RPMI 1640 with 5% FBS.
Cell lysis and Western Blot Analysis.
Cytoplasmic and nuclear extracts were prepared according to the procedure described previously. 20 Samples were boiled with NuPAGE LDS sample buffer (Invitrogen), resolved on 4-12% NuPAGE Novex Bis-Tris Gels (Invitrogen), and transferred to PVDF membrane. Detection was carried out with ECL-Plus detection reagent (GE Healthcare).
Membrane Fraction and Immunoprecipitation.
Membrane preparations were carried out according to the procedure described by Woods et al.. 21 Briefly, cells were resuspended in 1ml hypotonic buffer containing 10 mM TrisHCl (pH 8.0), 1 mM MgCl 2, 5 µ g/mL E-64, 1 mM PMSF, 1 mM NaVO 4 and 1 mM NaF.
Cell suspensions were incubated on ice for 30 min before homogenization. NaCl was added to the homogenates to bring the final concentration of 150 mM and the samples were centrifuged at 210xg for 10min. The supernatants were diluted with 3 ml isotonic buffer containing 0.6M NaCl, 5 µ g/ml E-64, 1 mM PMSF, 1 mM NaVO 4 and 1 mM NaF, and were centrifuged at 100,000xg for 45min. The pellet was resuspended in hypotonic buffer containing 150 mM NaCl and 0.5% Triton X-100, and sonicated for 1 min. After centrifugation at 14,000 rpm for 10 min, the supernatants were collected as membrane Detection was carried out with ECL-Plus detection reagent.
RT-PCR
The complementary DNA was generated from 2 µg of RNA using the SuperScript III reverse transcription kit and random hexamers (Invitrogen) according to the manufacturer's procedure. For PCR reaction (20 µl), 1µl cDNA, 1.25U Taq DNA Polymerase (New England Biolabs, Inc.), 0.25mM each dNTP (New England Biolabs, Inc.) and 500nM of the respective TβRII primers were used. All samples were subjected to RT-PCR for the housekeeping gene GAPDH, which served as an internal standard.
RT-PCR products were resolved on 1% agarose gel in 1x TAE buffer, visualized by ethidium bromide, and photographed using image system (Alpha Innotech, San Leandro, 
Transient Transfection.
Cytomegalovirus (CMV) promoter-based expression plasmids for wild type TβRII and C-terminal truncated form of TβRII (∆cyt) were gifts from Dr. Joan Massague (Memorial Sloan-Kettering Cancer Center, New York). 22 Exponentially growing DB cells (5x10 6 /point) were transfected with 3 µg TβRII (WT) or TβRII (∆cyt) plasmid using
Nucleofector Kit V (Amaxa Inc., Gaithersburg, Maryland) according to the manufacturer's protocol. Cells were then exposed to electroporation using program T-27.
After incubation for 12 hours, cells were transferred to RPMI 1640 with 5% FBS, and stimulated with PMA/TGF-β for various time point.
5'-azacytidine Treatment
Cells were seeded at a density of 0.5 x 10 6 /ml. 5-azacytidine was added to the medium for final concentration of 2 µM for 7 days. At every 24h interval, serum-free medium containing 5'-azacytidine was added. Cells were allowed to recover for 24h in complete medium without 5'-azacytidine at 37 o C in 5% CO 2 .
Sodium Bisulfite Modification
Genomic DNAs from lymphoma cells were modified using a method described previously. 23, 24 Briefly, 1µg DNA in a volume of 18 µl was denatured by adding 18 µl 0.6M sodium hydroxide and incubated for 10min at 37 
Methylation-specific PCR (MSP)
In the first round PCR, DNA was amplified using the universal primers (Forward: 
Results
Effects of TGF-β on proliferation of two B-cell lymphoma cell lines, RL and DB
It has been previously shown that RL and DB cells do not express TGF-β receptors on their cell surface, but treatment with a low dose of PMA induced the expression of TGF-β receptors on their cell surface. 25 To determine the effect of TGF-β treatment on the proliferative response of these cell lines, RL and DB cells were treated with PMA and TGF-β for various periods of time, and the proliferation was measured by cell counts. As shown in Fig. 1 , while PMA treatment alone had no effect on the proliferative response of either cell type, addition of TGF-β to the PMA-treated cells caused a significant growth suppression of RL cells. In contrast, TGF-β treatment had no effect on the growth of DB cells.
Examination of the TGF-β signaling in RL and DB cells
To examine the molecular mechanism underlying the unresponsiveness of DB cells to TGF-β treatment, we first assessed the integrity of the TGF-β signaling pathway in this cell line. We examined the kinetics of nuclear translocation of phospho-Smad3 and phospho-Smad2 upon TGF-β treatment. RL and DB cells were pretreated with PMA for 18 hours, after which TGF-β was added to the culture for various periods of time. While western blot analysis of the nuclear extracts of RL cells revealed the up-regulation of nuclear phospho-Smad3, no phospho-Smad3 was detected in the nuclear extracts of DB cells (Fig. 2) . Similarly, no nuclear translocation of phospho-Smad2 was observed in DB cells, whereas the TGF-β-induced nuclear translocation of phospho-Smad2 was quite significant in RL cells (Fig. 2) . When the membranes were stripped and reprobed with either anti-Smad3 or anti-Smad2 antiserum, basal levels of both Smad3 and Smad2 were observed in the nuclear extracts of DB cells. These data suggested that the lack of TGF-β signaling could be responsible for the unresponsiveness of DB cells to TGF-β treatment.
Status of nuclear p21
Cip1/WAF1 and c-Myc in DB and RL cells
To further investigate whether lack of nuclear translocation of phospho-Smads could account for the unresponsiveness of DB cells to TGF-β-mediated growth suppression, we checked the status of nuclear p21 Cip1/WAF1 (hereafter referred to as p21) and c-Myc, two TGF-β-responsive genes. 26 As shown in (Fig. 4a) . The lack of interaction was not due to 
Effect of ectopically expressed TβRII in DB cells
If the lack of TβRII is responsible for the unresponsiveness of DB cells to TGF-β-mediated growth suppression, re-introduction of TβRII should render DB cells responsive to TGF-β treatment, unless a truncated version of the receptor is acting in a dominant negative fashion. To investigate the ability of TβRII to restore TGF-β responsiveness, we expressed either wild type or a c-terminal truncated version of receptor II that lacked kinase activity in DB cells. As shown in Fig. 5a , ectopically expressed wild type, but not c-terminal truncated receptor II, rendered DB cells Cip1/WAF1 and down regulation of c-Myc, two TGF-β-responsive genes, in the wild type receptor II transfected DB cells only (Fig. 5c ). Collectively, these data strongly suggested that the lack of TβRII at the cell surface might be responsible for the unresponsiveness of DB cells to TGF-β treatment.
Examination of the TβRII gene in B-cell lymphoma cell lines.
In order to determine whether DB cells completely lacked TβRII message, or these cells carried a modified form of TβRII message, attempts were made to amplify full length TβRII cDNA by RT-PCR using total RNAs from DB and RL cells. Although we were able to amplify the full length TβRII cDNA from RL cells, no PCR product was obtained from DB cells (Fig. 6a) . To determine whether there is any mutation in TβRII gene in DB cells, all seven exons of TβRII gene were amplified and DNA sequencing was was unique in DB cells, we tested another B-cell lymphoma cell line Akata, which has been shown to be resistant to TGF-β-mediated growth suppression and lacks TβRII protein. 7 Treatment with 5'-azacytidine also resulted in the expression of TβRII message in Akata cells (Fig. 6b) . RL and BJAB, two B-cell lymphoma cell lines that are responsive to TGF-β-mediated growth suppression and have functional TβRII, were used as a positive control (Fig. 6b) . To determine the status of promoter methylation, CpG sites at -140 and -25 of TβRII gene were analyzed by methylation specific and unmethylation specific primers using bisulfite-modified DNA. As shown in Fig. 6c , both DB and Akata cells were positive for methylation-specific primers corresponding to both promoter sites, which were reversed after 5'-azacytidine treatment, indicating that both sites were methylated in DB and Akata cells, and the methylation status was reversed after 5'-azacytidine treatment. TGF-β-responsive cell lines RL and BJAB, which harbor functional TβRII, were negative for methylation-specific primers, whereas they were positive for unmethylated-specific primers (Fig. 6c) . Next, we wanted to determine 
Discussion.
In this report, we describe a mechanism by which some tumor cells can avoid TGF-β-mediated growth suppression. A diffuse large B-cell lymphoma cell line, DB, which is refractory to TGF-β-mediated growth suppression, lacks TβRII on its cell surface, while maintaining a normal level of TβRI. On the other hand, another diffuse large B-cell lymphoma cell line, RL, which is susceptible to TGF-β-mediated growth suppression, has a normal level of both TβRI and TβRII. The finding that DB cells lack TβRII at its cell surface is in apparent contradiction with our previous finding where we observed the The TβRII gene is a frequent target for mutational inactivation in colorectal cancers with microsatellite instability. 11, 12 Microsatellite stable colon cancers have also been shown to harbor mutations in TβRII gene. 10 Mutations were found within a polyadenine tract in colorectal cancers with microsatellite instability, which affected both alleles of TβRII gene. 11 Human colon cancer cell lines with high rates of microsatellite instability have also been shown to carry mutated TβRII resulting in the absence of cell surface receptor II, and small amounts of RII transcripts. 27 Missense mutations in TβRII gene have also been found in two human squamous head and neck carcinoma cell lines. 28 Both mutations were located within the conserved serine-threonine kinase domain. 28 Expression of TβRII gene has also been shown to be the target of the EWSR1-FLI1 fusion gene product in Ewing sarcoma. 29 Both fusion positive Ewing sarcoma cell lines and primary tumors have been shown to express low or undetectable levels of TβRII mRNA and protein product. 29 Mutations at the TGF-β receptor complex have been reported to be involved in escape mutant responsible for progression of lymphomatoid papulosis to systemic lymphoma. 30 Promoter methylation has also been shown to be responsible for the aberrant expression of TβRII gene in primary non-small cell lung cancer and prostate cancer cells 31, 32 , and prostate and lung cancer cell lines.
33,34
An examination of the study by Alizadeh et. al. 18 , identified TβRII as one of the T-Smad2 
Figure 6
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